13-cis-retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma

Cancer. 1991 May 15;67(10):2490-4. doi: 10.1002/1097-0142(19910515)67:10<2490::aid-cncr2820671017>3.0.co;2-q.

Abstract

A 35-year-old man with refractory cutaneous Ki-1 lymphoma was salvaged successfully with oral 13-cis-retinoic acid (1 mg/kg/day). He had a complete remission lasting for 20 months before a single nodule recurred on his skin. Excisional biopsy of the recurrent tumor revealed a distinct morphologic change, suggesting cellular differentiation toward a more benign phenotype. No significant side effects were noted except mild xerostomia, bone pain, and hyperlipidemia. The authors believe that 13-cis-retinoic acid should be considered in the treatment of cutaneous Ki-1 lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antigens, Differentiation
  • Antigens, Neoplasm
  • Cell Differentiation / drug effects
  • Humans
  • Immunophenotyping
  • Ki-1 Antigen
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / immunology
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Male
  • Remission Induction
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Tretinoin / adverse effects
  • Tretinoin / therapeutic use*

Substances

  • Antigens, Differentiation
  • Antigens, Neoplasm
  • Ki-1 Antigen
  • Tretinoin